PGLYRP1 and neoplasm: In mammals, PGLYRP1 is mainly produced by neutrophils in antibacterial granules, also regulating innate immunity,27 28 or by epithelial cells to modulate the microbiome.29–31 Recently, PGLYRP1 was associated with immune evasive mechanisms in T cells from certain tumours (ie, melanoma), positioning it as a potential target for cancer treatment.32 However, to date, PGLYRP1 has not been studied in PDAC or in PDAC CSCs.